ICON Announces the Expansion of its Accellacare Site Network
10 Novembro 2021 - 6:02PM
Business Wire
New partnerships increase geographical footprint, supporting
more access to patients and strengthening therapeutic
capability
ICON plc, (NASDAQ: ICLR) a global provider of drug development
and commercialisation services to pharmaceutical, biotechnology,
medical device, and government organisations, today announced that
its Accellacare Site Network has expanded in reach and capabilities
through new partnerships with six research sites across four
countries.
Agreements with Asclepes Research and Olympian Clinical Research
in the United States, Curiositas ad Sanum and Intermed in Germany,
Quironsalud in Spain, and KO-MED in Poland brings the Accellacare
network to 112 active locations across eight countries and the
entry to two new U.S. states – Florida and California. Through
these new partnerships, Accellacare is also enhancing its
already-strong capability in the central nervous system (CNS) and
immune-inflammation therapeutic areas.
The expansion of the Accellacare Site Network increases access
and engagement with investigative sites and its patients,
supporting faster recruitment and reducing the overall time and
cost associated with drug development for customers. Accellacare
now has access to more than 9 million patients.
“Enrolling and engaging patients in clinical trials continues to
be one of the biggest challenges within drug development,” said
Alison Liddy, Senior Vice President, Site & Patient Solutions
at ICON. “Our new Accellacare partnerships extend our ability to
help customers enhance clinical trial feasibility and improve
patient enrollment timelines in key therapeutic areas. We are
committed to enhancing engagement with sites, patients and
healthcare providers to reduce the overall time and costs of
clinical development programmes for our customers.”
ICON launched Accellacare, a global clinical research network,
in September 2020, providing patients easier and faster access to
innovative treatments and offering customers the option to deploy
decentralised trials. For customers, this approach leads to higher
patient recruitment and retention rates, which generates
operational efficiencies, accelerates study start-up timelines, and
enhances study feasibility.
“As the clinical trial industry evolves past the COVID-19
pandemic, it is more important than ever to ensure we have a strong
partner to continue to enable growth at our sites,” said Tim Welke,
owner of Asclepes Research Centers. “Over the last several months,
Accellacare has been a valuable member of our operation, allowing
us to have more studies to offer our patients. Accellacare’s
commitment and support to our site and each study aligns with our
mission of improving patient care.”
# # #
About ICON plc and Accellacare ICON is a world-leading
healthcare intelligence and clinical research organisation. From
molecule to medicine, we advance clinical research providing
outsourced development and commercialisation services to
pharmaceutical, biotechnology, medical device and government and
public health organisations. We develop new innovations, drive
emerging therapies forward and improve patient lives. With
headquarters in Dublin, Ireland, ICON operates from 159 locations
in 53 countries and has approximately 37,960 employees as of
September 30, 2021. For more information, visit
www.iconplc.com.
Accellacare is a global clinical research network
incorporating the Accellacare Site Network, In-Home Services and
Site Resourcing. The Accellacare Site Network extends to 112 active
research sites in eight countries with expertise in a wide range of
therapeutic areas. It has relationships with more than 300
Principal Investigators, which connects the network to 9 million
patients across its footprint. For more information, visit
www.accellacare.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211110005896/en/
Media Contacts: Laurie Hurst Sr Director, Public
Relations & Communications, ICON plc +1 919-274-3189
Laurie.Hurst@iconplc.com
Weber Shandwick (PR adviser) Lisa Henry (GMT time zone) +447785
458203 lhenry@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024